These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
128 related articles for article (PubMed ID: 7153754)
1. Enhancement of non-specific resistance to Pseudomonas pneumonia by a synthetic derivative of muramoyl dipeptide in immunosuppressed guinea pigs. Osada Y; Ohtani T; Une T; Ogawa H; Nomoto K J Gen Microbiol; 1982 Oct; 128(10):2361-70. PubMed ID: 7153754 [TBL] [Abstract][Full Text] [Related]
2. Stimulation of non-specific resistance to infection by muroctasin. Otani T; Une T; Osada Y Arzneimittelforschung; 1988 Jul; 38(7A):969-76. PubMed ID: 3056426 [TBL] [Abstract][Full Text] [Related]
3. Restoration by MDP-Lys (L18) of resistance to Pseudomonas pneumonia in immunosuppressed guinea pigs. Otani T; Katami K; Une T; Osada Y; Ogawa H Microbiol Immunol; 1984; 28(9):1077-82. PubMed ID: 6513814 [No Abstract] [Full Text] [Related]
4. Role of alveolar macrophages in the neutrophil-dependent defense system against Pseudomonas aeruginosa infection in the lower respiratory tract. Amplifying effect of muramyl dipeptide analog. Ozaki T; Maeda M; Hayashi H; Nakamura Y; Moriguchi H; Kamei T; Yasuoka S; Ogura T Am Rev Respir Dis; 1989 Dec; 140(6):1595-601. PubMed ID: 2513762 [TBL] [Abstract][Full Text] [Related]
5. [Role of alveolar macrophages and neutrophils in the defense system against infection of Pseudomonas aeruginosa in the respiratory tract and the effect of derivative of muramyl dipeptide]. Maeda M; Ozaki T; Yasuoka S; Ogura T Nihon Kyobu Shikkan Gakkai Zasshi; 1990 Jan; 28(1):135-42. PubMed ID: 2355674 [TBL] [Abstract][Full Text] [Related]
6. Effect of MDP-Lys(L18), a derivative of MDP, on enhancing host resistance against Hantaan virus infection in newborn mice. Yoo YC; Yoshimatsu K; Hatsuse R; Tamura M; Yoshida R; Tono-oka S; Arikawa J; Azuma I Vaccine; 1995 Oct; 13(14):1300-5. PubMed ID: 8585284 [TBL] [Abstract][Full Text] [Related]
7. Effect of L18-MDP(Ala), a synthetic derivative of muramyl dipeptide, on nonspecific resistance of mice to microbial infections. Osada Y; Mitsuyama M; Une T; Matsumoto K; Otani T; Satoh M; Ogawa H; Nomoto K Infect Immun; 1982 Jul; 37(1):292-300. PubMed ID: 6809630 [TBL] [Abstract][Full Text] [Related]
8. Effect of muramyl dipeptide and its stearoyl derivatives on resistance to Sendai virus infection in mice. Ishihara C; Hamada N; Yamamoto K; Iida J; Azuma I; Yamamura Y Vaccine; 1985 Dec; 3(5):370-4. PubMed ID: 2417426 [TBL] [Abstract][Full Text] [Related]
9. Protective effect of MDP-Lys(L18), a synthetic derivative of muramyldipeptide, on murine cytomegalovirus infection. Eizuru Y; Nakagawa N; Hamasuna R; Minamishima Y Nat Immun; 1992; 11(4):225-36. PubMed ID: 1384831 [TBL] [Abstract][Full Text] [Related]
10. Activation of immune responses by muroctasin. Akasaki M Arzneimittelforschung; 1988 Jul; 38(7A):976-7. PubMed ID: 3056427 [TBL] [Abstract][Full Text] [Related]
11. Macrophages are stimulated by muramyl dipeptide to induce polymorphonuclear leukocyte accumulation in the peritoneal cavities of guinea pigs. Nagao S; Nakanishi M; Kutsukake H; Yagawa K; Kusumoto S; Shiba T; Tanaka A; Kotani S Infect Immun; 1990 Feb; 58(2):536-42. PubMed ID: 2298491 [TBL] [Abstract][Full Text] [Related]
12. Synergistic generation of tumoricidal macrophages by muroctasin and interferon-gamma. Nagao S; Sato K; Osada Y Arzneimittelforschung; 1988 Jul; 38(7A):999-1002. PubMed ID: 3142490 [TBL] [Abstract][Full Text] [Related]
13. General pharmacological properties of muroctasin. Kojima H; Hirohashi M; Kasai Y; Takasuna K; Fukumoto C; Akashi A Arzneimittelforschung; 1988 Jul; 38(7A):1002-9. PubMed ID: 3190791 [TBL] [Abstract][Full Text] [Related]
14. Immunostimulant activities of a lipophilic muramyl dipeptide derivative and of desmuramyl peptidolipid analogs. Parant MA; Audibert FM; Chedid LA; Level MR; Lefrancier PL; Choay JP; Lederer E Infect Immun; 1980 Mar; 27(3):826-31. PubMed ID: 7380554 [TBL] [Abstract][Full Text] [Related]
15. Augmentation of immune responses by a muramyl dipeptide analog, MDP-Lys(L18). Akasaki M; Takashi T; Kita Y; Tsukada W Agents Actions; 1987 Oct; 22(1-2):144-50. PubMed ID: 3318323 [TBL] [Abstract][Full Text] [Related]
16. Chemical modification of the C-6 substituent in the carbohydrate moiety of N-acetylmuramoyl-L-alanyl-D-isoglutamine (MDP), and the immunoadjuvant activity. Okumura H; Tokushima Y; Saiki I; Azuma I; Kiso M; Hasegawa A Carbohydr Res; 1983 Oct; 122(1):87-98. PubMed ID: 6652634 [TBL] [Abstract][Full Text] [Related]
17. Antigenicity study of muroctasin. Yamaguchi F; Hattori H; Wagai N; Tsukada W Arzneimittelforschung; 1988 Jul; 38(7A):1034-7. PubMed ID: 3190797 [TBL] [Abstract][Full Text] [Related]
18. Acute and chronic polyarthritis induced by an aqueous form of 6-O-acyl and N-acyl derivatives of N-acetylmuramyl-L-alanyl-D-isoglutamine in euthymic rats and athymic nude rats. Kohashi O; Kohashi Y; Shigematsu N; Ozawa A; Kotani S Lab Invest; 1986 Sep; 55(3):337-46. PubMed ID: 3489128 [TBL] [Abstract][Full Text] [Related]
19. Production of colony-stimulating factor from macrophages by muroctasin. Yamaguchi F; Akahane K; Takashi T; Tsukada W Arzneimittelforschung; 1988 Jul; 38(7A):983-6. PubMed ID: 3263870 [TBL] [Abstract][Full Text] [Related]
20. Correlation between in vivo anti-Pseudomonas and anti-Candida activities and clearance of carbon by the reticuloendothelial system for various muramyl dipeptide analogs, using normal and immunosuppressed mice. Fraser-Smith EB; Waters RV; Matthews TR Infect Immun; 1982 Jan; 35(1):105-10. PubMed ID: 7054119 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]